EAACI Guidelines on Allergen Immunotherapy: Executive Statement

A. Muraro, G Roberts, S. Halken, A Agache, L. Angier, M. Fernandez Rivas, Roy Gerth van Wijk, M. Jutel, S Lau, Giovanni Pajno, Oliver Pfaar, D Ryan, Gunter J Sturm, R. Van Ree, Eva M Varga, C. Bachert, M. J. Calderon, G W Canonica, S. R. Durham, Hans J MallingU. Wahn, A Sheikh

Research output: Contribution to journalEditorialpeer-review

Abstract / Description of output

The allergist's community has recently celebrated 100 year of Allergen Immunotherapy (AIT). Unfortunately the implemention of this treatment is still impaired by some challenges. With the diversity of definitions, methodology and different allergen products used, research studies have produced conflicting outcomes. This has resulted in confusion about the benefits and risks of AIT amongst policymakers and professionals, as well as in the variable availability of AIT products, regulation and reimbursement policies globally. In 2015 EAACI initiated the AIT Guidelines project as part of the Presidential plan in order to settle the controversies. This article is protected by copyright. All rights reserved.

Original languageEnglish
Early online date30 Jan 2018
Publication statusPublished - Apr 2019

Keywords / Materials (for Non-textual outputs)

  • Editorial


Dive into the research topics of 'EAACI Guidelines on Allergen Immunotherapy: Executive Statement'. Together they form a unique fingerprint.

Cite this